PCDHA4: A Promising Drug Target and Biomarker for Prostate Cancer

Target Name: PCDHA4

NCBI ID: G56144

PCDHA4

PCDHA4: A Promising Drug Target and Biomarker for Prostate Cancer

Prostate cancer is one of the most common cancers worldwide, with an estimated 12.8 million new cases and 9 million deaths in 2020, according to the World Health Organization (WHO). The development of new treatments and biomarkers for prostate cancer is crucial for improving treatment outcomes and increasing survival rates. PCDHA4, a protein known as Protocadherin alpha-4 (isoform 2), has emerged as a promising drug target and biomarker for prostate cancer.

PCDHA4 is a transmembrane protein that plays a critical role in cell-cell adhesion and tissue organization. It is a member of the cadherin family, which is known for their ability to promote cell-cell adhesion and formation of tight junctions, which are essential for tissue organization and development. In addition to its role in cell-cell adhesion, PCDHA4 has also been shown to regulate various cellular processes, including cell growth, apoptosis, and angiogenesis.

As a drug target, PCDHA4 has the potential to inhibit its functions and disrupt its role in cancer progression. Several studies have shown that PCDHA4 can be a promising drug target for prostate cancer. PCDHA4 has been shown to promote the growth and survival of prostate cancer cells in cell culture and animal models. Additionally, several inhibitors of PCDHA4 have been shown to negatively affect the growth and survival of prostate cancer cells in vitro and in vivo.

As a biomarker, PCDHA4 can be used as a target for diagnostic and prognostic studies in prostate cancer. The expression of PCDHA4 has been shown to be associated with various aspects of prostate cancer progression, including cancer stage, grade, and recurrence. Additionally, some studies have shown that PCDHA4 expression is associated with poor prognosis in prostate cancer patients, with higher PCDHA4 expression levels being associated with poor survival outcomes.

In conclusion, PCDHA4 is a promising drug target and biomarker for prostate cancer. Its functions in cell-cell adhesion and tissue organization make it an attractive target for inhibitors that can disrupt its role in cancer progression. Further research is needed to fully understand the role of PCDHA4 in prostate cancer and its potential as a drug target and biomarker.

Protein Name: Protocadherin Alpha 4

Functions: Calcium-dependent cell-adhesion protein involved in cells self-recognition and non-self discrimination. Thereby, it is involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets